Eflornithine, also known by the trade name Vaniqa when used in dermatology, is an irreversible inhibitor of the enzyme ornithine decarboxylase (ODC). By blocking ODC, eflornithine reduces polyamine synthesis, which is essential for cell proliferation. The compound is a synthetic analogue of the naturally occurring polyamine spermidine and is administered as the hydrochloride salt.
Chemical and pharmacological properties
- IUPAC name: (E)-N-(2,2-dimethylpropyl)-2-(prop-2-enoylamino)pentanamide hydrochloride
- Molecular formula: C₉H₁₈N₂O·HCl
- Molar mass: 207.71 g·mol⁻¹ (free base)
- Mechanism of action: Irreversibly binds to the active site of ODC, leading to long‑lasting inhibition of polyamine synthesis. This effect underlies its antiproliferative activity against trypanosomes and its ability to slow hair follicle growth.
Medical uses
| Indication | Formulation | Route of administration | Typical dosage |
|---|---|---|---|
| Human African trypanosomiasis (sleeping sickness) – late‑stage disease caused by Trypanosoma brucei gambiense | Injectable solution of eflornithine hydrochloride | Intravenous infusion | 400 mg/kg/day divided into four doses over 24 h for 14 days (standard regimen) |
| Facial hirsutism (excessive hair growth) | Topical cream (0.5 % w/w) | Topical application to affected skin | Twice daily; results typically observed after 8 weeks of continuous use |
The drug is included in the World Health Organization’s list of essential medicines for the treatment of sleeping sickness. In dermatology, it is marketed in several countries for the cosmetic reduction of unwanted facial hair.
History and development
Eflornithine was first synthesized in the 1970s by scientists at the pharmaceutical company Hoechst AG. Initial clinical investigations focused on its antiparasitic activity against Trypanosoma species. In 1990, the drug received approval from the United States Food and Drug Administration (FDA) for the treatment of African trypanosomiasis. The topical formulation for hirsutism was later approved by the FDA in 2000 under the brand name Vaniqa.
Pharmacokinetics
- Absorption: Poor oral bioavailability; thus, systemic treatment requires intravenous administration. The topical formulation achieves localized skin concentrations with minimal systemic exposure.
- Distribution: Widely distributes in plasma; low penetration across the blood‑brain barrier, which limits its efficacy in the early (hemolymphatic) stage of sleeping sickness.
- Metabolism: Minimal hepatic metabolism; the compound is primarily excreted unchanged.
- Elimination: Renal excretion accounts for the majority of drug clearance; half‑life is approximately 1–2 hours after intravenous dosing.
Adverse effects
Commonly reported adverse events during intravenous therapy for trypanosomiasis include neutropenia, thrombocytopenia, anemia, and elevated liver enzymes. Severe toxicity is rare but may involve renal impairment or hypersensitivity reactions. Topical use is generally well tolerated; local skin irritation, erythema, and dryness are the most frequent complaints.
Regulatory status
- United States: Prescription‑only (Rx) for both indications.
- European Union: Authorized for both antiparasitic and dermatological indications under national marketing authorizations.
- World Health Organization: Included in the Model List of Essential Medicines (antiparasitic category).
Research and experimental uses
Beyond its approved indications, eflornithine has been investigated in clinical trials as an adjunct therapy for certain cancers (e.g., colorectal and melanoma) due to its anti‑proliferative properties. Results to date have been mixed, and the drug has not received regulatory approval for oncologic use.
See also
- Ornithine decarboxylase inhibitors
- African trypanosomiasis
- Polyamine metabolism
References
(References would be listed here in a formal encyclopedic entry, citing peer‑reviewed journals, FDA drug approval documents, WHO guidelines, and pharmacology textbooks.)